IGUP20133 / Van Veldhuizen / ARC-6
Basic Study Information
Purpose:Location: Wilmot Cancer Institute Oncology, University of Rochester
This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor
activity and safety of etrumadenant (AB928)-based combination therapy in participants
with metastatic castrate resistant prostate cancer (mCRPC).
Lead Researcher (Principal Investigator)
Peter Van Veldhuizen
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search